Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC

被引：9
|
作者：
Piotrowska, Zofia
Liu, Stephen V.
Muzikansky, Alona
Marcoux, Nicolas
Banwait, Mandeep
Stevens, Sara
Goodwin, Kelly
Lafferty, Tracey E.
Ackil, Jennifer
Krueger, Elizabeth A.
Heist, Rebecca Suk
Lin, Jessica Jiyeong
Gainor, Justin F.
Hata, Aaron N.
Shaw, Alice Tsang
Sequist, Lecia V.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Harvard Med Sch, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21231
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21231
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A new standard for EGFR-mutant NSCLC?
    Killock, David
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (10) : 593 - 593
  • [42] EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
    Niina Laurila
    Jussi P. Koivunen
    Medical Oncology, 2015, 32
  • [43] A new standard for EGFR-mutant NSCLC?
    David Killock
    Nature Reviews Clinical Oncology, 2019, 16 : 593 - 593
  • [44] Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions
    Rotow, J.
    Patel, J.
    Hanley, M.
    Yu, H.
    Goldman, J.
    Nechustan, H.
    Scheffler, M.
    Awad, M.
    Clifford, S.
    Santucci, A.
    Silva, L.
    Tupper, R.
    Oxnard, G.
    Kherani, J.
    Drilon, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S230 - S230
  • [45] Amivantamab Plus Lazertinib vs Osimertinib in Firstline EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study
    Gadgeel, S.
    Cho, B. C.
    Lu, S.
    Felip, E.
    Hayashi, H.
    Spira, A. I.
    Besse, B.
    Thomas, M.
    Owen, S.
    Kim, Y. J.
    Lee, S. -H.
    Dias, J. Mourao
    Lee, Y. -G.
    Zhao, Y.
    Fang, Y.
    Girard, N.
    Liu, Z.
    Sun, P.
    Oliveira, S. C. Sousa
    Shen, H.
    Paz-Ares, L.
    Matsumoto, S.
    Tanaka, H.
    Ahmad, A. R.
    Andabekov, T.
    Sunpaweravong, P.
    Ozyilkan, O.
    Yang, J. C. -H.
    Gottfried, M.
    Hernandez, O.
    Kimmich, M.
    Cortinovis, D.
    Kaen, D. L.
    Montes, L. V. Garcia
    Popat, S.
    Newsom-Davis, T.
    Xie, J.
    Sun, T.
    Fennema, E.
    Daksh, M.
    Ennis, M.
    Sethi, S.
    Bauml, J. M.
    Nguyen, D.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S10 - S11
  • [46] Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC:An ETCTN California cancer consortium phase I study.
    Riess, Jonathan W.
    Groshen, Susan G.
    Reckamp, Karen L.
    Wakelee, Heather A.
    Oxnard, Geoffrey R.
    Padda, Sukhmani Kaur
    Koczywas, Marianna
    Piotrowska, Zofia
    Sholl, Lynette M.
    Paweletz, Cloud P.
    Lau, Christie J.
    Kolesar, Jill
    Mack, Philip C.
    Moscow, Jeffrey
    Janne, Pasi A.
    Lara, Primo
    Newman, Edward M.
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC
    Wang, Kaiwen
    Du, Robyn
    Myall, Nathaniel J.
    Lewis, Whitney E.
    Uy, Natalie
    Hong, Lingzhi
    Skoulidis, Ferdinandos
    Byers, Lauren A.
    Tsao, Anne
    Cascone, Tina
    Pozadzides, Jenny
    Tu, Janet
    Negrao, Marcelo, V
    Gibbons, Don L.
    Park, Keunchil
    Rinsurongkawong, Waree
    Lee, J. Jack
    Gandara, David
    Behl, Deepti
    Shu, Catherine A.
    Riess, Jonathan W.
    Baik, Christina
    Wakelee, Heather A.
    Vaporciyan, Ara A.
    Heymach, John, V
    Zhang, Jianjun
    Le, Xiuning
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 500 - 506
  • [48] CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC
    Hui, C.
    Wakelee, H. A.
    Neal, J. W.
    Ramchandran, K. J.
    Das, M.
    Nagpal, S.
    Roy, M.
    Huang, J.
    Pollom, E.
    Myall, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E110 - E110
  • [49] Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC "
    Chen, Ching-Yi
    Wang, Guo-Sheng
    Wei, James Cheng-Chung
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (05) : e6 - e7
  • [50] Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC
    Remon, Jordi
    Hendriks, Lizza E. L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 368 - 370
12345